



ABN 53 075 582 740

**ASX ANNOUNCEMENT**  
**20 November 2014**

---

## **BNC101 DATA TO BE PRESENTED AT EUROPEAN CANCER CONFERENCE**

Bionomics Limited (ASX:BNO, ADR:BMICY) is presenting a poster on cancer stem cell antibody BNC101 at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona.

The four day symposium attracts approximately 2,000 academics, scientists and pharmaceutical industry professionals from around the world. The event is co-hosted by European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR) with participants discussing innovations in drug development, target selection and new discoveries in molecular biology.

Bionomics' poster, *Targeting colorectal and pancreatic cancer stem cells with the LGR5 monoclonal antibody BNC101*, will present new data such as the activity of BNC101 in primary lung cancer and additional triple negative breast models. It concludes that BNC101 may improve patient outcomes in colorectal cancer, pancreatic cancer and other solid tumours. The poster will be part of today's session titled *Molecular Targeted Agents I*.

BNC101 is a monoclonal antibody that targets cancer stem cells, a subset of cells within a tumour thought to play a critical role in tumour initiation, recurrence and metastasis. Eliminating cancer stem cells, in conjunction with other therapies that address the tumour bulk, represents a new cancer treatment paradigm that could offer a distinct advantage over existing strategies and a solution for chemoresistance.

BNC101 has successfully completed IND-enabling studies with a view to conducting Phase I clinical studies in the near term. The BNC101 therapeutic strategy is to delay recurrence and/or metastatic disease by preventing cancer stem cells from re-seeding cancer following front-line surgery and standard of care chemotherapy.

BNC101 is also highly effective when combined with standard of care chemotherapy treatments in these solid tumours.

### **FOR FURTHER INFORMATION PLEASE CONTACT:**

**Bionomics Limited**  
Dr Deborah Rathjen  
CEO & Managing Director  
+618 8354 6101 /  
0418 160 425  
[drathjen@bionomics.com.au](mailto:drathjen@bionomics.com.au)

**Monsoon Communications**  
Rudi Michelson  
+613 9620 3333  
[rudim@monsoon.com.au](mailto:rudim@monsoon.com.au)

**The Trout Group**  
Lauren Glaser  
+1 646 378 2972  
[lglaser@troutgroup.com](mailto:lglaser@troutgroup.com)

## **About Bionomics Limited**

Bionomics (ASX: BNO) is biopharmaceutical company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, memory loss and pain. Its oncology approach includes cancer stem cell therapeutics as well as vascular disruption in solid tumours.

Bionomics' discovery and development activities are driven by its four proprietary technology platforms: MultiCore®, a diversity orientated chemistry platform for the discovery of small molecule drugs; ionX®, a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system; Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels); and CSC Rx Discovery™, which identifies antibody and small molecule therapeutics that inhibit the growth of cancer stem cells. These platforms drive Bionomics' pipeline and underpin its established business strategy of securing partners for its key compounds. Bionomics partners include Merck & Co.

[www.bionomics.com.au](http://www.bionomics.com.au)

## **Factors Affecting Future Performance**

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' development candidates BNC105, BNC210, BNC101 and BNC375, our acquisition of Eclipse Therapeutics and ability to develop products from their platform, its licensing deals with Merck & Co, drug discovery programs and pending patent applications are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, Merck's decisions to continue or not to continue development of partnered compounds, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Results of studies performed on competitors products may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.